openPR Logo
Press release

US Orphan Drug Pipeline Analysis

06-30-2017 12:21 PM CET | Health & Medicine

Press release from: PNS Pharma

In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry. With close to 30 million people in the US having some kind of rare disease complaints, the increasing activities around the development of orphan drugs only imply that the appropriate treatments for unmet needs are increasing, thus increasing the profit margins in the future.

Download Report:

http://www.pnspharma.com/buy-report.php?reporttitle=US-Orphan-Drug-Pipeline-Analysis

“US Orphan Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various orphan designated drugs being developed for the treatment of rare disease. Research report covers all the orphan designated drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the US Orphan Drug market based upon development process.

Following parameters for each drug profile in development phase are covered in “US Orphan Drug Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes

US Orphan Drug Pipeline by Clinical Phase:

• Research: 4

• Preclinical: 54

• Phase-I: 68

• Phase-I/II: 62

• Phase-II: 169

• Phase-II/III: 15

• Phase-III: 93

• Preregistration: 28

• Registration: 18

• Marketed: 137

For Report Sample Contact: rajesh@pnspharma.com or :Visit :
https://www.pnspharma.com

Recent Publication

* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release US Orphan Drug Pipeline Analysis here

News-ID: 603616 • Views: 186

More Releases from PNS Pharma

Gene Therapy Market witnessing 35% Growth To Reach USD 8 Billion By 2026
The approach of modifying the genes directly to correct the disease linked with it is one of the most widely accepted and researched field in the pharmaceutical industry. Gene therapy holds significant potential to support various applications in the cancer research sector and other genetic linked diseases. The promising and potential approach of the therapy to treat numerous genetic diseases is making it a successful research sector. Another important potential
Global Gene Therapy Market To Witness Positive Outlook With More Than USD 8 Bill …
Gene therapy process has successfully gained popularity among the researchers all around the globe. Since its discovery, the primary driver of the market of the gene therapy process is considered to be its ability to alter the cause of the disease at the molecular level and that too precisely than the other available technologies. The technological advancements and the development in the gene delivery systems have developed a bright scope
Global Gene Therapy Market Size Sales To Surpass USD 8 Billion By 2026
" Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlights: o Global Gene Therapy market Opportunity: > USD 8 Billion o Global Gene Therapy Pipeline:: > 1000 In Trials o Commercially Available Gene Therapies: 11 o US & Europe Are Key Markets Download Report: http://pnspharma.com/buy-report.php?reporttitle=Global-Gene-Therapy-Market-Opportunity-%26-Clinical-Trials-Insight-2026 1. Introduction to Gene Therapy 1.1 Gene Therapy: An Overview 1.2 History of Development 2. Gene Therapy & its Impact on Genetic Alterations 2.1 Gene Therapy as a Mastermind of Genetic Revolution
Global Breast Cancer Drug Market & Clinical Trial Insight 2025
" Global Breast Cancer Drug Market & Clinical Trial Insight 2025" Report Highlights: • Global Breast Cancer Drug Market: US$ 40 Billion Opportunity • Global Breast Cancer Drug Clinical Pipeline: More Than 550 Drugs • Marketed Breast Cancer Drugs: More Than 90 Drugs • Comprehensive Clinical Insight & Patent Information • Drug Trials, Pricing, Dosage, Cancer Prevalence Insight: 130 Graphs/Charts Download Report: http://pnspharma.com/buy-report.php?reporttitle=Global-Breast-Cancer-Drug-Market-%26-Clinical-Trial-Insight-2025 The applied science research has marked tremendous advancements in cutting off the epidemic cancer scenarios all around the

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning